Home LiteratureArticle Details
PMID: 1245600 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus.

The Journal of clinical investigation ·Vol. 57 ·No. 1 ·1976-01-00 ·Pages 212-21

Schrager MA, Rothfield NF

Abstract

61 biopsies of normal skin from the deltoid area and lesional skin from various sites from 48 patients with systemic lupus erythematosus (SLE) were studied for the presence of properdin, C3, C4, and immunoglobulins (IgG, IgM, and IgA) in the dermal-epidermal junction (DEJ) using direct and indirect immunofluorescence. Properdin was present in 50% of normal and 40% of lesional skins. Properdin was present without C4 in only 2 of 38 nonlesional skin biopsies and in only 2 of 20 lesions. There was no significant difference in incidence of deposition of any of the six proteins studied between nonlesional and lesional skin. The frequency of deposition of each of the proteins correlated with clinical disease activity. The presence of proteins in the DEJ did not correlate with the presence of active renal disease at the time of biopsy nor with previously documented active nephritis. In addition, no other single clinical manifestation correlated with the presence of DEJ deposition of any protein studied. IgA was not demonstrated in the DEJ of nonlesional skin of 16 patients in remission and was present in 7 of 23 patients with active disease (P less than 0.05). Deposition of properdin in lesional skin correlated with the presence of extracutaneous disease activity (P less than 0.05). Analysis of serologic studies on serum obtained at the time of biopsy revealed a statistically significant correlation between C4 and C3 (r = 0.67). This correlation was stronger than that between properdin and C4 (r = 0.37). Titer of antinuclear antibody and percent of DNA binding correlated better with C4 levels than with properdin levels. Serum properdin levels were significantly lower in patients with active disease than in those in remission (P less than 0.05). Serum properdin levels were significantly lower in patients with properdin deposits in lesional skin than in those without properdin deposits. The data suggest that both alternative and classical pathways are activated in patients with clinically active SLE.

MeSH Terms
Adolescent Adult Child Complement C3/analysis Complement C4/analysis Female Humans Immunoglobulin A/analysis Immunoglobulin G/analysis Immunoglobulin M/analysis Lupus Erythematosus, Systemic/blood,immunology Male Middle Aged Properdin/analysis Skin/immunology
Chemicals
Complement C3 Complement C4 Immunoglobulin A Immunoglobulin G Immunoglobulin M Properdin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Schrager M A
Rothfield N F
References (42)
42 references, click to expand
  1. Properties of highly purified human properdin.
    J Immunol. 1968 Jan;100(1):142-58 PMID: 4169693
  2. The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins.
    J Immunol. 1970 Feb;104(2):329-34 PMID: 4189670
  3. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.
    J Exp Med. 1973 Dec 1;138(6):1305-13 PMID: 4202731
  4. Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level.
    Clin Immunol Immunopathol. 1973 Nov;2(1):16-27 PMID: 4204416
  5. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
    J Exp Med. 1974 May 1;139(5):1249-61 PMID: 4207623
  6. Properdin levels in systemic lupus erythematosus and membranoproleferative glomerulonephritis.
    Clin Exp Immunol. 1974 Apr;16(4):575-81 PMID: 4219766
  7. Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid.
    J Clin Invest. 1973 Jul;52(7):1779-87 PMID: 4352464
  8. Hydroxyapatite chromatography and formamide denaturation of adenovirus DNA.
    J Virol. 1973 Aug;12(2):218-25 PMID: 4355929
  9. Studies on the sub-unit structure of human properdin.
    Immunochemistry. 1974 Jul;11(7):361-8 PMID: 4477550
  10. Immunofluorescent skin test in systemic lupus erythematosus. Lack of relationship with renal disease.
    JAMA. 1972 Nov 20;222(8):935-7 PMID: 4570136
  11. Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis.
    Br Med J. 1973 Aug 11;3(5875):326-8 PMID: 4579400
  12. Patterns of nuclear fluorescence and DNA-binding activity.
    Ann Rheum Dis. 1973 Jul;32(4):337-41 PMID: 4580007
  13. Immunoglobulin in clinically uninvolved skin in systemic lupus erythematosus: association with renal disease.
    J Clin Invest. 1974 May;53(5):1434-40 PMID: 4596508
  14. Skin immunofluorescence studies on lupus erythematosus and other antinuclear-antibody-positive diseases.
    Ann Intern Med. 1974 Apr;80(4):496-500 PMID: 4621260
  15. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.
    N Engl J Med. 1972 Oct 26;287(17):835-40 PMID: 4627271
  16. Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.
    J Clin Invest. 1973 Mar;52(3):634-44 PMID: 4630981
  17. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).
    Immunology. 1973 Feb;24(2):259-75 PMID: 4632688
  18. The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.
    J Exp Med. 1973 Feb 1;137(2):424-37 PMID: 4734403
  19. Solid phase radioimmunoassay of properdin.
    Immunochemistry. 1973 May;10(5):341-50 PMID: 4738906
  20. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
    J Clin Invest. 1974 Jun;53(6):1578-87 PMID: 4830223
  21. Dermal-epidermal deposition of complement components and properdin in systemic lupus erythematosus.
    Br J Dermatol. 1975 Mar;92(3):263-71 PMID: 1096924
  22. Cutaneous immunopathology: recent observations.
    J Invest Dermatol. 1975 Jul;65(1):143-53 PMID: 1097540
  23. The significance of cutaneous immunoglobulin deposits in lupus erythematosus and NZB/NZW F1 hybrid mice.
    J Invest Dermatol. 1975 Jul;65(1):154-61 PMID: 1097541
  24. Metabolism of properdin in normal subjects and patients with renal disease.
    J Clin Invest. 1975 Sep;56(3):761-7 PMID: 1159085
  25. The immunofluorescent "band" test for lupus erythematosus. 3. Employing clinically normal skin.
    Arch Dermatol. 1971 Jan;103(1):24-32 PMID: 4099590
  26. The C3-activator system: an alternate pathway of complement activation.
    J Exp Med. 1971 Sep 1;134(3 Pt 2):90s-108s PMID: 4105810
  27. C3 proactivator convertase and its mode of action.
    J Exp Med. 1972 Apr 1;135(4):1003-8 PMID: 4111773
  28. Electroimmuno assay.
    Scand J Clin Lab Invest Suppl. 1972;124:21-37 PMID: 4114358
  29. Glomerular and dermal depostion of properdin in systemic lupus erythematosus.
    N Engl J Med. 1972 Oct 5;287(14):681-5 PMID: 4115613
  30. An immunofluorescent study of the skin lesions in systemic lupus erythematosus.
    Arthritis Rheum. 1966 Feb;9(1):37-46 PMID: 4143707
  31. Immunoglobulin class and pattern of nuclear fluorescence in systemic lupus erythematosus.
    N Engl J Med. 1966 Jun 16;274(24):1333-8 PMID: 4160639
  32. Immunological studies concerning the nephritis of systemic lupus erythematosus.
    J Exp Med. 1967 Oct 1;126(4):607-24 PMID: 4168098
  33. Immunologic factors and clinical activity in systemic lupus erythematosus.
    N Engl J Med. 1968 Mar 7;278(10):533-8 PMID: 4866347
  34. Complement in human disease.
    Annu Rev Med. 1968;19:1-24 PMID: 4871687
  35. Immunofluorescent techniques in clinical diagnosis of cutaneous disease.
    Ann Intern Med. 1969 Oct;71(4):753-62 PMID: 4902576
  36. The clinical course of the proliferative and membranous forms of lupus nephritis.
    Ann Intern Med. 1970 Dec;73(6):929-42 PMID: 4947941
  37. Functional relationship of factor B in the properdin system to C3 proactivator of human serum.
    J Immunol. 1971 Oct;107(4):1200-4 PMID: 5093780
  38. Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia.
    J Clin Invest. 1971 Mar;50(3):642-9 PMID: 5545124
  39. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.
    Science. 1954 Aug 20;120(3112):279-85 PMID: 13186838
  40. THE APPLICATION OF THE FLUORESCENT ANTIBODY TECHNIC TO THE INVESTIGATION OF LUPUS ERYTHEMATOSUS AND VARIOUS DERMATOSES.
    J Invest Dermatol. 1963 Dec;41:451-6 PMID: 14085466
  41. "BOUND" GLOBULIN IN THE SKIN OF PATIENTS WITH CHRONIC DISCOID LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS.
    Lancet. 1964 Mar 7;1(7332):534-5 PMID: 14100191
  42. Relation of positive L.E.-cell preparations to activity of lupus erythematosus and corticosteroid therapy.
    N Engl J Med. 1962 Mar 15;266:535-8 PMID: 14494433
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI108262
Published
1976-01-00
Pages
212-21
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC436641
Subset
IM
External Links
PubMed source DOI: 10.1172/JCI108262 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2